BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cox N, Tillmann H. Emerging pipeline drugs for hepatitis B infection. Expert Opin Emerg Drugs 2011;16:713-29. [PMID: 22195605 DOI: 10.1517/14728214.2011.646260] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Cox NR, Patel K, Tillmann HL. A Rationalized Approach to the Treatment of Patients Infected with Hepatitis B. Mol Diagn Ther 2014;18:203-12. [DOI: 10.1007/s40291-013-0072-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Chang M. Children need optimal management of chronic hepatitis B. Nat Rev Gastroenterol Hepatol 2013;10:505-6. [DOI: 10.1038/nrgastro.2013.137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
3 Nguyen MH, Lim JK, Burak Ozbay A, Fraysse J, Liou I, Meyer N, Dusheiko G, Gordon SC. Advancing Age and Comorbidity in a US Insured Population-Based Cohort of Patients With Chronic Hepatitis B. Hepatology. 2019;69:959-973. [PMID: 30175482 DOI: 10.1002/hep.30246] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 9.3] [Reference Citation Analysis]
4 Levi M, Falla A, Taddei C, Ahmad A, Veldhuijzen I, Niccolai G, Bechini A. Referral of newly diagnosed chronic hepatitis B and C patients in six EU countries: results of the HEPscreen Project. Eur J Public Health 2016;26:561-9. [PMID: 27095794 DOI: 10.1093/eurpub/ckw054] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
5 Hu Y, Zhu W, Tang G, Mayweg AV, Yang G, Wu JZ, Shen HC. Novel Therapeutics in Discovery and Development for Treatment of Chronic HBV Infection. Elsevier; 2013. pp. 265-81. [DOI: 10.1016/b978-0-12-417150-3.00017-x] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
6 Feng S, Gao L, Han X, Hu T, Hu Y, Liu H, Thomas AW, Yan Z, Yang S, Young JAT, Yun H, Zhu W, Shen HC. Discovery of Small Molecule Therapeutics for Treatment of Chronic HBV Infection. ACS Infect Dis 2018;4:257-77. [PMID: 29369612 DOI: 10.1021/acsinfecdis.7b00144] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
7 Edwards TC, Lomonosova E, Patel JA, Li Q, Villa JA, Gupta AK, Morrison LA, Bailly F, Cotelle P, Giannakopoulou E, Zoidis G, Tavis JE. Inhibition of hepatitis B virus replication by N-hydroxyisoquinolinediones and related polyoxygenated heterocycles. Antiviral Res 2017;143:205-17. [PMID: 28450058 DOI: 10.1016/j.antiviral.2017.04.012] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
8 Ladhani SN, Flood JS, Amirthalingam G, Mieli-vergani G, Bansal S, Davison S, Naik S, Riordan A, Shingadia D, Tudor-williams G, Sira J, Kelly DA, Ramsay ME. Epidemiology and Clinical Features of Childhood Chronic Hepatitis B Infection Diagnosed in England. Pediatric Infectious Disease Journal 2014;33:130-5. [DOI: 10.1097/inf.0000000000000196] [Cited by in Crossref: 8] [Article Influence: 1.0] [Reference Citation Analysis]
9 Villa JA, Pike DP, Patel KB, Lomonosova E, Lu G, Abdulqader R, Tavis JE. Purification and enzymatic characterization of the hepatitis B virus ribonuclease H, a new target for antiviral inhibitors. Antiviral Res 2016;132:186-95. [PMID: 27321664 DOI: 10.1016/j.antiviral.2016.06.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
10 Lu G, Villa JA, Donlin MJ, Edwards TC, Cheng X, Heier RF, Meyers MJ, Tavis JE. Hepatitis B virus genetic diversity has minimal impact on sensitivity of the viral ribonuclease H to inhibitors. Antiviral Res 2016;135:24-30. [PMID: 27693161 DOI: 10.1016/j.antiviral.2016.09.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
11 Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, Kann M, Knolle PA, Benkirane M, Durantel D, Michel M, Autran B, Cosset F, Strick-marchand H, Trépo C, Kao J, Carrat F, Lacombe K, Schinazi RF, Barré-sinoussi F, Delfraissy J, Zoulim F. Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure. Gut 2015;64:1314-26. [DOI: 10.1136/gutjnl-2014-308943] [Cited by in Crossref: 186] [Cited by in F6Publishing: 178] [Article Influence: 26.6] [Reference Citation Analysis]
12 Huang C, Lin HH, Wan JB, He C, Hu Y. Research and Development of Hepatitis B Drugs: An Analysis Based on Technology Flows Measured by Patent Citations. PLoS One 2016;11:e0164328. [PMID: 27727319 DOI: 10.1371/journal.pone.0164328] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
13 Huber AD, Michailidis E, Tang J, Puray-Chavez MN, Boftsi M, Wolf JJ, Boschert KN, Sheridan MA, Leslie MD, Kirby KA, Singh K, Mitsuya H, Parniak MA, Wang Z, Sarafianos SG. 3-Hydroxypyrimidine-2,4-Diones as Novel Hepatitis B Virus Antivirals Targeting the Viral Ribonuclease H. Antimicrob Agents Chemother 2017;61:e00245-17. [PMID: 28320718 DOI: 10.1128/AAC.00245-17] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
14 Hu Y, Cheng X, Cao F, Huang A, Tavis JE. β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity. Antiviral Research 2013;99:221-9. [DOI: 10.1016/j.antiviral.2013.06.007] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 6.8] [Reference Citation Analysis]
15 Edwards TC, Mani N, Dorsey B, Kakarla R, Rijnbrand R, Sofia MJ, Tavis JE. Inhibition of HBV replication by N-hydroxyisoquinolinedione and N-hydroxypyridinedione ribonuclease H inhibitors. Antiviral Research 2019;164:70-80. [DOI: 10.1016/j.antiviral.2019.02.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
16 Xu H, Wu Q, Peng C, Zhou L. Study on the antiviral activity of San Huang Yi Gan Capsule against hepatitis B virus with seropharmacological method. BMC Complement Altern Med 2013;13:239. [PMID: 24073917 DOI: 10.1186/1472-6882-13-239] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
17 Tavis JE, Lomonosova E. The hepatitis B virus ribonuclease H as a drug target. Antiviral Res. 2015;118:132-138. [PMID: 25862291 DOI: 10.1016/j.antiviral.2015.04.002] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 6.9] [Reference Citation Analysis]
18 Tavis JE, Cheng X, Hu Y, Totten M, Cao F, Michailidis E, Aurora R, Meyers MJ, Jacobsen EJ, Parniak MA, Sarafianos SG. The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes. PLoS Pathog 2013;9:e1003125. [PMID: 23349632 DOI: 10.1371/journal.ppat.1003125] [Cited by in Crossref: 79] [Cited by in F6Publishing: 78] [Article Influence: 8.8] [Reference Citation Analysis]
19 Huber AD, Pineda DL, Liu D, Boschert KN, Gres AT, Wolf JJ, Coonrod EM, Tang J, Laughlin TG, Yang Q, Puray-Chavez MN, Ji J, Singh K, Kirby KA, Wang Z, Sarafianos SG. Novel Hepatitis B Virus Capsid-Targeting Antiviral That Aggregates Core Particles and Inhibits Nuclear Entry of Viral Cores. ACS Infect Dis 2019;5:750-8. [PMID: 30582687 DOI: 10.1021/acsinfecdis.8b00235] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]